The market is making some investors nervous, but you don’t have to give up tech altogether to make your portfolio safer.
These three dividend beasts stand apart from the crowd.
The Latin American e-commerce giant is going places.
Shares fall hard in response to an analyst downgrade. Here's what investors need to know.
Traders are feeling giddy after management shared the bull case for owning its stock at an important investor conference.
Declining revenue growth rates might not have pleased traders, but it wasn't a bad year for the business.
It was a banner year for the medical device maker.
Traders cheer after the company reports pleasing preliminary results for the fourth quarter and shares bullish guidance.
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Shares jumped after the company provided investors with a slew of positive updates. Here are the key takeaways for investors.
Shares jumped more than 66% in response to news that the company is being acquired. Here's what investors need to know.
This business truly has it all.
Looking for income stocks that promise dividend growth? Check out these three.
Shares tumble in response to an industry megamerger.
Shares tumble on a slow news day. What can explain the double-digit move?
Shares jump in response to a buyout offer.
These scrawny stocks are bargains that should have investors licking their lips.
Shares soar after the company announces that it's being taken private. Did Christmas come a day early for shareholders?
Investors in the cancer-focused medical device company have enjoyed strong returns already. Is it too late to hop on board?
Find out why a medical device maker, a gene sequencer, and a drug licensing company have our team of healthcare experts feeling bullish.